Skip to the content
Please enable JavaScript in your browser to complete this form.
Quiz
Please complete the quiz on or before 22 August 2022 (Monday). We shall submit the CME accreditation for you after your submission of the quiz.
1. Which patient of the below is most likely to have the highest fracture risk?
*
1.
*
a) Patient with a recent clinical or radiographic vertebral fracture
b) Patient with BMD T-score -2.0
and
no fracture history
c) Patient on oral bisphosphonate for 3 years
2. Which of the below best described patients who should be considered for initial treatment with Anabolic Agents?
*
2.
*
a) Patients with 10-year major osteoporotic fracture risk at 10% at computed by FRAX
b) Patients who cannot tolerate oral bisphosphonates
c) Patients with very low BMD (T-score <-3)
3. Which of the below description is NOT correct about the effect of bone forming agents?
*
3.
*
a) Teriparatide might be effective in fracture healing, but further study is needed to confirm the benefit
b) Osteoporosis condition affects surgical outcome in patients with fracture
c) There are NO existing clinical studies showing bone forming agents could improve fusion rates
4. Which of the below description is correct when patients stopped anti-osteoporosis therapies (e.g. denosumab, alendronate, teriparatide) without subsequent treatments?
*
4.
*
a) BMD T-score of the patients would always remain unchanged
b) Patients would have higher risks of getting clinical fractures
c) Treatment holiday could be life-long and fracture risk would not increase
5. Which of the below osteoporosis management approaches is the most appropriate to prevent fractures in patients?
*
5.
*
a) Treatment holiday should be recommended after 3 years of anti-osteoporosis therapies, no matter which medication was prescribed
b) Evaluate patients’ fracture risks solely by BMD T-score
c) Orthopaedic surgeons should embrace the patient’s osteoporosis condition and perform a BMD check-up prior to surgeries
First Name:
*
Last Name:
*
Email:
*
– The end –
Submit